Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.2K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.6K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.9K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.9K
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

320
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
320
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

250
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
250
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.6K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant immunotherapy in breast cancer: Progress and challenges.

Trends in cancer·2026
Same author

Integration of sarcopenia screening into radiotherapy planning: Validation of a time-efficient SMI measurement method using MIM software in prostate cancer.

Journal of applied clinical medical physics·2026
Same author

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial.

Nature medicine·2026
Same author

Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.

Frontiers in immunology·2026
Same author

Image-guided brachytherapy in patients with inoperable FIGO 2009 stage IVB endometrial cancer who were not candidates for palliative surgery.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Dual-energy and perfusion CT for predicting response to chemo-radiotherapy in head and neck cancer: an exploratory study.

Frontiers in oncology·2026

Related Experiment Video

Updated: Feb 11, 2026

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
05:46

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

2.2K

Dose-response in choroidal melanoma.

Alex De Caluwé1, Karolien Termote2, Dirk Van Gestel1

  • 1Department of Radiation Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|April 23, 2018
PubMed
Summary

A minimum tumor dose of 65 Gy is crucial for durable local control in choroidal melanoma treatment. This study establishes a dose-response relationship, guiding future radiotherapy trials for this rare eye cancer.

Keywords:
BrachytherapyCharged particle external beam radiotherapyChoroidal melanomaDose-response relationshipTumor Control Probability (TCP)

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K
Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.6K

Related Experiment Videos

Last Updated: Feb 11, 2026

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
05:46

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

2.2K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K
Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.6K

Area of Science:

  • Ophthalmology
  • Radiation Oncology
  • Medical Physics

Background:

  • Choroidal melanoma is a rare intraocular malignancy.
  • The optimal radiation dose for local control is not well-established.
  • Understanding dose-response is critical for effective treatment strategies.

Purpose of the Study:

  • To investigate the dose-response relationship for local control in choroidal melanoma.
  • To determine the radiation threshold dose required for tumor eradication.
  • To compare findings with existing brachytherapy and external beam radiotherapy data.

Main Methods:

  • Retrospective analysis of 135 choroidal melanoma patients treated with Strontium-90 (Sr-90).
  • Minimum tumor dose (Dmin) ranged from 0 Gy to 287 Gy.
  • Local failure as the primary endpoint, analyzed using competing risk methods.

Main Results:

  • A Dmin of ≥65 Gy was independently associated with favorable local control (p=0.04).
  • Tumor distance from the optic disc was also a significant factor (p<0.001).
  • Scleral dose, tumor diameter, and height did not significantly impact local failure rates.

Conclusions:

  • This study provides the first dose-response data for choroidal melanoma with a wide Dmin range.
  • A Dmin of 65 Gy is necessary for achieving durable tumor response.
  • These findings can inform the design of future clinical trials for choroidal melanoma radiotherapy.